Columbia Wanger Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Columbia Wanger Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-416,200	Closed	-$37.6M	–	219
2014 Q4	$37.6M	Sell	416,200 -437,600	-51%	-$36.4M	0.19%	173
2014 Q3	$61.6M	Sell	853,800 -314,000	-27%	-$20.6M	0.28%	125
2014 Q2	$72.6M	Sell	1,167,800 -221,200	-16%	-$13.4M	0.29%	124
2014 Q1	$94.7M	Sell	1,389,000 -656,000	-32%	-$48.3M	0.37%	88
2013 Q4	$144M	Sell	2,045,000 -315,292	-13%	-$21.4M	0.55%	49
2013 Q3	$170M	Sell	2,360,292 -339,708	-13%	-$22.6M	0.69%	36
2013 Q2	$151M	Buy	+2,700,000	New	+$168M	0.66%	35

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Columbia Wanger Asset Management's BMRN Position: Q1 2015 in Review

Columbia Wanger Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2015, closing a stake of 416,200 shares — an estimated $37.6M sold.

Columbia Wanger Asset Management first reported a position in BMRN in Q2 2013 and held it in 7 quarters. The position peaked at $170M in Q3 2013. 377 funds tracked by Wall St. Rank hold BMRN as of Q1 2015.

Columbia Wanger Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Columbia Wanger Asset Management sold 416,200 BioMarin Pharmaceuticals shares in Q1 2015, an estimated $37.6M.
Columbia Wanger Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Columbia Wanger Asset Management's BioMarin Pharmaceuticals position peaked at $170M in Q3 2013.
377 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2015.

Based on Columbia Wanger Asset Management's 13F filing for Q1 2015, filed 1 May 2015.